Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- LDP’s Health Committee Demands Enhanced R&D Tax Break as Key Priority
November 24, 2016
- MHLW OKs Janssen’s HIV Combo Pill Prezcobix
November 24, 2016
- AMED to Allocate 240 Million Yen for R&D of Innovative Cancer Treatments, Including CAR-T Cell Therapy
November 24, 2016
- MHLW to Announce Opdivo’s New Prices on Nov. 24
November 24, 2016
- MHLW to Revise Rules on Development Requests for Unapproved Drugs
November 22, 2016
- Council OKs Public Knowledge-Based Application for Tamiflu’s New Pediatric Dosage
November 22, 2016
- MHLW to Set Up Quake-Resistant Warehouse to Stockpile Vaccines Using Supplementary Budget for FY2016
November 21, 2016
- MHLW to Kick Off Discussions for Major Drug Pricing Overhaul by Year-End: Bureau Chief
November 18, 2016
- MOF Panel Budget Recommendation Calls for Curbing Drug Costs
November 18, 2016
- 10 APIs/17 Products to Join NHI Price List on Nov. 18
November 17, 2016
- Chuikyo Floats Reimbursement Claims Based on “Amount Used” in Lieu of “Vial Units”
November 17, 2016
- Doctor, Industry Reps Get in Spat over Indication Additions: Chuikyo
November 17, 2016
- 50% Price Cut for Opdivo OK’ed with Estimated Sales of 151.6-Plus Billion Yen
November 17, 2016
- ICH Eyes Major GCP Revamp with Use of Real World Data: Osaka Confab
November 16, 2016
- 3 Immunosuppressants to Be Discussed for Lifting of Contraindicated Pregnancy Use
November 16, 2016
- Opdivo’s NHI Price-Based Sales Put at Over 151 Billion Yen; 50% Cut Likely to Take Effect Feb. 1
November 15, 2016
- MHLW Advisory Committee to Review Biogen’s MS Drug on Nov. 25
November 14, 2016
- Opdivo Gets MHLW Panel Nod for Hodgkin’s Lymphoma
November 14, 2016
- MHLW Panel to Discuss NSCLC Indication for Keytruda on Nov. 24
November 14, 2016
- LDP Study Group on Biologics to Hold 1st Meeting on Nov. 24; Aims to Halt the Rush to Promote Biosimilars
November 11, 2016
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…